|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A multivariate analysis suggested that MET positivity may still be prognostic for worse median overall survival in gastric cancer; therefore, it is important to continue investigation into the optimal approach to inhibit MET signaling in gastric cancer.
|
27401892 |
2016 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, the profile of the gastric cancer samples observed that sf-RON was frequently upregulated in MET-positive gastric cancer.
|
26528757 |
2015 |
|
Stomach Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Finally, we observed an inverse correlation between the expression of miR-144 and MET mRNA in GC metastatic tissues.
|
25927670 |
2015 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
c-Met targeting in advanced gastric cancer: An open challenge.
|
26049023 |
2015 |
|
Stomach Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Approximately 10 - 20% of gastric cancer presented an increased MET gene copy numbers; inappropriate activation of MET promotes cellular proliferation, cell motility, invasiveness and angiogenesis and is associated with more aggressive phenotype and with a lower survival.
|
25881479 |
2015 |
|
Stomach Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Moreover, we found that levels of PAX3 and MET were positively correlated in matched human GC specimens, and their coexpression was associated with poor prognoses.
|
25653235 |
2015 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mechanistically, miR-449c may target MET to suppress GC cell growth.
|
26141986 |
2015 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We also showed that HOTAIR recruiting and binding to PRC2 epigenetically represses miR34a, which controls the targets C-Met (HGF/C-Met/Snail pathway) and Snail, thus contributing to GC cell-EMT process and accelerating tumor metastasis.
|
26136075 |
2015 |
|
Stomach Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, miR‑34a was associated with the clinicopathological features of gastric cancer and was a valuable predictor of patient prognosis. miR‑34a acted as a tumor suppressor to inhibit gastric cancer proliferation and invasion via the downregulation of MET.
|
26238271 |
2015 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Comprehensive genomic profiling of GC identifies clinically relevant GAs that suggest benefit from targeted therapy including MET-amplified GC and ERBB2 base substitutions.
|
25882375 |
2015 |
|
Stomach Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression.
|
25584489 |
2015 |
|
Stomach Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The findings from present study indicated that higher MET gene amplification and expression in gastric cancer was an indicator of poor prognosis.
|
24416238 |
2014 |
|
Stomach Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
MET rs40239 may serve as a prognostic biomarker in locoregional gastric cancer.
|
25203738 |
2014 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, this study suggests that MET mRNA expression assessed by RNA ISH could be useful as a potential marker to identify MET oncogene-addicted GC.
|
25364819 |
2014 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study aimed to explore the molecular segmentation of several known therapeutics targets, human epidermal growth factor receptor 2 (HER2), MET and fibroblast growth factor receptor 2 (FGFR2), within GC using clinically approved or investigational kits and scoring criteria.
|
24518603 |
2014 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, miR-34a may act as a potential tumour suppressor in gastric cancer and is associated with the mechanisms of gastric cancer metastasis; miR-34a can inhibit gastric cancer tumourigenesis by targeting PDGFR and MET through the PI3K (phosphoinositide 3-kinase)/Akt pathway.
|
24837198 |
2014 |
|
Stomach Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
To investigate methods for assessing MET overexpression in gastric cancer, we conducted immunohistochemistry using a new anti-Total MET monoclonal antibody in a single-institution cohort of 495 patients.
|
23807774 |
2013 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
C-Met as a prognostic marker in gastric cancer: a systematic review and meta-analysis.
|
24223894 |
2013 |
|
Stomach Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Paracrine activation of MET promotes peritoneal carcinomatosis in scirrhous gastric cancer.
|
24118504 |
2013 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Multivariate analysis revealed that MACC-1 and c-MET may be independent prognostic indexes of gastric carcinoma (P < 0.01).
|
23812675 |
2013 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The median MET copy number in 266 cases of gastric cancer was 1.7, with a range of 0.41 to 21.3.
|
23327903 |
2013 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Also, the prognostic role of MET indicates that anti-MET therapy is a very promising modality in adjuvant treatment for gastric cancer.
|
22644302 |
2012 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therapeutic strategies that target the tyrosine kinase MET hold promise for gastric cancer, but the mechanism underlying the antitumor activity of such strategies remains unclear.
|
22729845 |
2012 |
|
Stomach Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This study assessed the incidence of MET expression and gene amplification in tumors of Western patients with gastric cancer.
|
21393565 |
2011 |
|
Stomach Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In this study, qPCR revealed approximately 10% of white patients with gastric cancer harboring MET CNG of five or more copies.
|
22042954 |
2011 |